Granitron

Granitron is a prescription medication that contains the active ingredient granisetron hydrochloride. It is supplied in an oral dosage form, with the specific strength not disclosed in the available data. Granisetron belongs to the 5‑HT3 receptor antagonist class and is used primarily as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative settings. The product is marketed within the European Union and requires a physician’s prescription.

Granitron is indicated for the prevention of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Adjunct therapy for patients receiving highly emetogenic chemotherapy regimens. - Use in combination with other antiemetic agents when single‑drug therapy is insufficient.

The safety profile of Granitron includes both frequently observed and less common adverse reactions.

Common: - Headache. - Constipation. - Diarrhea. - Fatigue.

Serious: - Severe allergic reaction such as anaphylaxis or angioedema. - Cardiac arrhythmia, including rare QT‑interval prolongation. - Serotonin syndrome when combined with other serotonergic agents.

Before initiating Granitron, healthcare providers should consider several precautionary factors.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use cautiously in patients with known prolonged QT interval or cardiac conduction disorders. - Evaluate renal or hepatic impairment, as dose adjustments may be required. - Monitor for signs of constipation or bowel obstruction, especially in postoperative patients. - Discuss pregnancy and breastfeeding status; safety data are limited. - Review concomitant use of other antiemetics to avoid overlapping toxicity.

Granitron may interact with other medications, influencing its efficacy or safety.

Avoid: - Other 5‑HT3 receptor antagonists (e.g., ondansetron) due to additive antiemetic effect. - Drugs known to prolong QT interval (e.g., certain antiarrhythmics, fluoroquinolones). - Monoamine oxidase inhibitors (MAOIs) when combined with serotonergic agents.

Use with caution: - Serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or tramadol. - Anticholinergic medications that may increase risk of constipation. - CYP3A4 inhibitors or inducers, although granisetron is minimally metabolized, monitoring is advised.